The Triple Marker Test is a prenatal blood screening typically conducted between the 15th and 20th week of pregnancy. It measures the levels of Alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and unconjugated estriol (uE3) in the mother’s blood to evaluate the risk of certain genetic disorders and birth defects in the fetus. These include Down syndrome (Trisomy 21), Edward’s syndrome (Trisomy 18), and neural tube defects like spina bifida. The test helps doctors identify pregnancies that may require further diagnostic procedures, such as amniocentesis, to confirm any potential abnormalities.